Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| PECKHAM, RICHARD GRANT | 1 | 67.2% | +37.0% |
| LEE, ANDREW P | 1 | 48.4% | +23.3% |
| KUCKLA, ANNA GRACE | 1 | 52.4% | +55.0% |
| ENGLISH, CONNOR KENNEDY | 1 | 55.8% | +54.3% |
| RODRIGUEZ, RAYNA B | 1 | 33.1% | +20.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 12d |
| 18505396 | METHODS OF TREATING MELANOMA WITH RIPRETINIB | LEE, ANDREW P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | 8d overdue |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 12d |
| 18457825 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | KUCKLA, ANNA GRACE | 42d |
| 18770318 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | KIFLE, BRUCK | — |
| 18683078 | COMBINATION THERAPY USING VPS34 INHIBITORS | PECKHAM, RICHARD GRANT | — |
| 18505396 | METHODS OF TREATING MELANOMA WITH RIPRETINIB | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1691 | 1 |
| 1626 | 1 |
| 1625 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18770318 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | KIFLE, BRUCK | — | DP | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18683078 | COMBINATION THERAPY USING VPS34 INHIBITORS | PECKHAM, RICHARD GRANT | 1627 | §102§103DP | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18505396 | METHODS OF TREATING MELANOMA WITH RIPRETINIB | LEE, ANDREW P | 1691 | §102§103 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18457825 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | 42d | Pending | Aug 29, 2023 |
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Final Rejection | 8d overdue | Pending | Dec 09, 2022 |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 1628 | §103§112 | Final Rejection | 12d | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial